MLL -Rearranged Acute Leukemia with t(4;11)(q21;q23)-Current Treatment Options. Is There a Role for CAR-T Cell Therapy?

The ( ) gene, located on chromosome 11q23, is involved in chromosomal translocations in a subtype of acute leukemia, which represents approximately 10% of acute lymphoblastic leukemia and 2.8% of acute myeloid leukemia cases. These translocations form fusions with various genes, of which more than 8...

Full description

Saved in:
Bibliographic Details
Published in:Cells (Basel, Switzerland) Switzerland), 2019-10, Vol.8 (11), p.1341
Main Authors: Britten, Oliver, Ragusa, Denise, Tosi, Sabrina, Kamel, Yasser Mostafa
Format: Article
Language:English
Subjects:
acute leukemia
Acute lymphoblastic leukemia
Acute myeloid leukemia
Adults
Age groups
car-t cell therapy
Cell therapy
Chemotherapy
Chromosome 11
Chromosome 4
chromosome translocation
Chromosome translocations
Chromosomes
Clinical outcomes
Cytotoxicity
Epigenetics
Gene expression
Gene mapping
Hematopoietic stem cells
Kinases
kmt2a
Leukemia
Lymphatic leukemia
Lymphocytes T
Medical prognosis
mixed-lineage leukemia
mll
mll-af4
Mutation
Myeloid leukemia
Patients
Pediatrics
Prognosis
Remission
Review
RNA polymerase
Stem cells
Transplants & implants
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The ( ) gene, located on chromosome 11q23, is involved in chromosomal translocations in a subtype of acute leukemia, which represents approximately 10% of acute lymphoblastic leukemia and 2.8% of acute myeloid leukemia cases. These translocations form fusions with various genes, of which more than 80 partner genes for have been identified. The most recurrent fusion partner in rearrangements ( -r) is , mapping at chromosome 4q21, accounting for approximately 36% of -r leukemia and particularly prevalent in -r acute lymphoblastic leukemia (ALL) cases (57%). -r leukemia is associated with a sudden onset, aggressive progression, and notoriously poor prognosis in comparison to non- -r leukemias. Despite modern chemotherapeutic interventions and the use of hematopoietic stem cell transplantations, infants, children, and adults with -r leukemia generally have poor prognosis and response to these treatments. Based on the frequency of patients who relapse, do not achieve complete remission, or have brief event-free survival, there is a clear clinical need for a new effective therapy. In this review, we outline the current therapy options for -r patients and the potential application of CAR-T therapy.
ISSN:2073-4409
2073-4409
DOI:10.3390/cells8111341